TRAF6 is a ubiquitin ligase that is essential for the activation of NF-kB and MAP kinases in several signalling pathways, including those emanating from the interleukin 1 and Toll-like receptors 1-3 . TRAF6 functions together with a ubiquitin-conjugating enzyme complex consisting of UBC13 (also known as UBE2N) and UEV1A (UBE2V1) to catalyse Lys 63-linked polyubiquitination, which activates the TAK1 (also known as MAP3K7) kinase complex 4,5 . TAK1 in turn phosphorylates and activates IkB kinase (IKK), leading to the activation of NF-kB. Although several proteins are known to be polyubiquitinated in the IL1R and Toll-like receptor pathways, it is not clear whether ubiquitination of any of these proteins is important for TAK1 or IKK activation. By reconstituting TAK1 activation in vitro using purified proteins, here we show that free Lys 63 polyubiquitin chains, which are not conjugated to any target protein, directly activate TAK1 by binding to the ubiquitin receptor TAB2 (also known as MAP3K7IP2). This binding leads to autophosphorylation and activation of TAK1. Furthermore, we found that unanchored polyubiquitin chains synthesized by TRAF6 and UBCH5C (also known as UBE2D3) activate the IKK complex. Disassembly of the polyubiquitin chains by deubiquitination enzymes prevented TAK1 and IKK activation. These results indicate that unanchored polyubiquitin chains directly activate TAK1 and IKK, suggesting a new mechanism of protein kinase regulation.
TRAF6 is a ubiquitin ligase that is essential for the activation of NF-kB and MAP kinases in several signalling pathways, including those emanating from the interleukin 1 and Toll-like receptors [1] [2] [3] . TRAF6 functions together with a ubiquitin-conjugating enzyme complex consisting of UBC13 (also known as UBE2N) and UEV1A (UBE2V1) to catalyse Lys 63-linked polyubiquitination, which activates the TAK1 (also known as MAP3K7) kinase complex 4, 5 . TAK1 in turn phosphorylates and activates IkB kinase (IKK), leading to the activation of NF-kB. Although several proteins are known to be polyubiquitinated in the IL1R and Toll-like receptor pathways, it is not clear whether ubiquitination of any of these proteins is important for TAK1 or IKK activation. By reconstituting TAK1 activation in vitro using purified proteins, here we show that free Lys 63 polyubiquitin chains, which are not conjugated to any target protein, directly activate TAK1 by binding to the ubiquitin receptor TAB2 (also known as MAP3K7IP2). This binding leads to autophosphorylation and activation of TAK1. Furthermore, we found that unanchored polyubiquitin chains synthesized by TRAF6 and UBCH5C (also known as UBE2D3) activate the IKK complex. Disassembly of the polyubiquitin chains by deubiquitination enzymes prevented TAK1 and IKK activation. These results indicate that unanchored polyubiquitin chains directly activate TAK1 and IKK, suggesting a new mechanism of protein kinase regulation.
To investigate the biochemical mechanism of TAK1 regulation, we reconstituted TAK1 activation in vitro using purified proteins, including E1, ubiquitin, UBC13-UEV1A (E2), TRAF6 (E3) and the TAK1-TAB1 (also known as MAP3K7IP1)-TAB2 kinase complex ( Fig. 1a , see Supplementary Information for the source and purification of the proteins). These proteins were incubated together with an ATP buffer, and the activation of TAK1 was analysed by immunoblotting with an antibody specific for TAK1 or TAK1 phosphorylated at Thr 187 (ref. 6) . As shown in Fig. 1b , in the presence of E1, UBC13-UEV1A, TRAF6 and ubiquitin, a slower migrating form of TAK1, which could be detected with the phosphorylated-TAK1 antibody, was apparent (lane 4). Phosphorylation of TAK1 was not detectable in the absence of E1, UBC13-UEV1A or TRAF6, or in the presence of ubiquitin mutants containing a mutation at Lys 63, which prevented polyubiquitin (polyUb)-chain synthesis. The phosphorylated form of TAK1 was converted to unphosphorylated TAK1 by lambda protein phosphatase ( Fig. 1c) , confirming that the large mobility shift of TAK1 was indeed caused by phosphorylation. These results demonstrate that TRAF6-catalysed Lys 63 polyubiquitination is both necessary and sufficient to activate TAK1 in vitro.
Two reactions occurred in the reconstitution system: ubiquitination and kinase activation. To uncouple these two steps, we first carried out the ubiquitination reaction in the presence of E1, ubiquitin, UBC13-UEV1A and TRAF6, but in the absence of the TAK1 kinase complex ( Fig. 2a ). The reaction mixtures were treated with N-ethylmaleimide (NEM)-an alkylating agent that inactivates E1 and E2. After NEM was quenched by dithiothreitol (DTT) and removed by buffer exchange, the ubiquitination mixtures were incubated with the TAK1 kinase complex in the presence of ATP. Remarkably, the ubiquitination product(s) synthesized in the first step was sufficient to activate the TAK1 kinase ( Fig. 2a , lane 6). This activation was not caused by ubiquitination of the TAK1 kinase complex, because E1 and E2 had been inactivated by NEM in step 1 before they encountered the TAK1 complex in step 2. Inactivation of E1 and E2 by NEM was complete, because after E1 and UBC13-UEV1A were incubated with NEM, they could no longer function together with TRAF6 to activate TAK1 in the second step (lanes 7-10). The activation of TAK1 correlated perfectly with the formation of polyUb chains-the synthesis of Bottom, the purified TAK1 kinase complex was incubated with E1, UBC13-UEV1A, TRAF6 and ubiquitin or its mutants in the presence of ATP for 1 h at 30 uC. Aliquots of the reaction products were analysed by immunoblotting (IB) with an antibody against TAK1, phosphorylated (p)-TAK1 or ubiquitin. c, TAK1 activated by TRAF6-catalysed ubiquitination as shown in b (lanes 3 and 4) was treated with lambda protein phosphatase and then analysed by immunoblotting. Numbers to the left of each gel denote kDa.
which required both UBC13-UEV1A and TRAF6. These results indicate that the polyubiquitination reaction in the first step produces an 'activator' that directly activates the TAK1 kinase complex.
A likely candidate that acts as the TAK1 activator is ubiquitinated TRAF6 (refs 4, 7). However, consistent with a previous report 8 , ubiquitinated TRAF6 was undetectable in the in vitro ubiquitination reactions containing varying concentrations of ubiquitin ( Fig. 2b and Supplementary Fig. 2 ). Despite the absence of detectable TRAF6 ubiquitination, the ubiquitination reaction stimulated TAK1 to phosphorylate MKK6 (also known as MAP2K6), a physiological substrate (Fig. 2b, lane 2) 4 . Furthermore, when the ubiquitination reaction mixtures were incubated with nickel-NTA agarose to separate Histagged proteins (including E1, UBC13-UEV1A and TRAF6) from the untagged protein (ubiquitin), most of the TAK1 stimulatory activity was present in the unbound fraction, which was largely depleted of TRAF6 (Fig. 2c, lane 3) . Therefore, the TAK1 stimulatory activity correlated with the polyUb chains, but not with TRAF6.
Next, we tried to identify the TAK1 activator in an unbiased manner by biochemical fractionation of TRAF6-catalysed ubiquitination mixtures (see Methods and the diagram in Fig. 2d ). The reaction mixtures were treated with NEM and then incubated with nickel-NTA agarose to deplete His-tagged proteins (E1, UBC13-UEV1A and TRAF6). The unbound material, which contained most of the TAK1 stimulatory activity, was further fractionated by gel filtration (Superdex-200) followed by cation exchange chromatography (Mono S). The fractions from the Mono-S column were assayed for their ability to activate TAK1 in the presence of ATP. The same fractions were also analysed by silver staining and immunoblotting with a ubiquitin antibody ( Fig. 2d) . Notably, the TAK1-stimulatory activity co-fractionated with high molecular mass polyubiquitinated species. Immunoblotting experiments with an antibody against TRAF6 or the His 6 -tag showed no detectable signal ( Supplementary Fig. 3 ), suggesting that the polyUb chains were not conjugated to any of these proteins. These 'unanchored' polyUb chains stimulated the TAK1 Step 2
Step 2 Ubiquitination ±UBC13-UEV1A ±TRAF6 a, Ubiquitination reaction was carried out in the presence of E1, UBC13-UEV1A, TRAF6 and ubiquitin, then E1 and E2 were inactivated with NEM (step 1) before incubation with the TAK1 complex in the presence of ATP to measure TAK1 activation (step 2). b, Ubiquitination reactions were carried out as in step 1 in a, then incubated with TAK1 and its substrate MKK6(Lys82Ala). c, Ubiquitination mixtures were incubated with nickel-NTA beads, then the bound and unbound fractions were tested for stimulation of TAK1. d, Left, the procedure for purification of TAK1 activator. Right, the Mono-S fractions were analysed for TAK1 activation and by silver staining and immunoblotting. e, Different concentrations of purified polyubiquitin chains (Mono-S fraction (fr.) 15 ) in panel d were tested for TAK1 activation. f, Lys 63and Lys 48-linked polyubiquitin chains were tested for TAK1 activation.
Numbers to the left of each gel denote kDa.
kinase to phosphorylate MKK6 in a dose-dependent and saturable manner ( Fig. 2e ). The concentration of polyUb chains required to achieve half-maximal activation of TAK1 was approximately 16 ng ml 21 . In contrast to Lys 63 polyUb chains, Lys 48-linked polyUb chains failed to activate TAK1 (Fig. 2f ).
To demonstrate further that unanchored Lys 63 polyUb chains were responsible for TAK1 activation, we incubated the purified polyUb chains with the deubiquitination enzymes CYLD or isopeptidase T (also known as IsoT or USP5). CYLD is a tumour suppressor protein exhibiting deubiquitination enzyme (DUB) activity that specifically cleaves Lys 63-linked polyUb 9,10 , whereas IsoT specifically cleaves unanchored polyUb from the proximal end owing to its high-affinity binding to the C-terminal tail of ubiquitin 11 . As shown in Fig. 3a , both CYLD and IsoT effectively converted Lys 63 polyUb chains into monoUb, and completely blocked the activation of TAK1. In contrast, a catalytically inactive CYLD mutant (Cys601Ser) was unable to cleave Lys 63 polyUb chains or inhibit TAK1. These results demonstrate that unanchored Lys 63 polyUb chains directly activate TAK1 in vitro.
To determine whether unanchored polyUb chains are synthesized in IL1b-stimulated cells, we used a TAB2 antibody to immunoprecipitate the TAK1 complex and associated polyUb chains from HEK293 activate TAK1. a, Purified polyUb chains were pre-incubated with the indicated enzymes and then tested for TAK1 activation. b, HEK293T-IL1R cells were stimulated with IL1b before cell lysates were immunoprecipitated (IP) with a TAB2 antibody. The precipitated materials were incubated with IsoT and then analysed by immunoblotting. Ub n , polyubiqutinated. c, A model of polyUb-induced TAK1 autophosphorylation. d, Purified polyUb was incubated with the wild-type TAK1 and/or TAK1(Lys63Trp) complexes in the presence of ATP. CBP, calmodulin-binding peptide. e, TAK1 complexes containing wild-type (WT) or a Cys670Ala/Cys673Ala (C . A) mutant of TAB2 were incubated with polyUb and MKK6(Lys82Ala) to measure TAK1 activation. Cue, coupling ubiquitin to endoplasmic reticulum degradation. f, Similar to e, except that the TAK1 complexes contained wild-type or Thr187Ala mutant of TAK1. Numbers to the left of each gel denote kDa.
cells stably expressing IL1R, which were stimulated with IL1b for different lengths of time (Fig. 3b) 12 . The TAB2-associated proteins were treated with IsoT, then immunoblotted with an antibody against ubiquitin, IRAK1 or TRAF6. Consistent with previous reports 4, 7, 13, 14 , IRAK1 and TRAF6 were rapidly polyubiquitinated after stimulation of cells with IL1b, but the polyUb chains on these proteins were resistant to disassembly by IsoT, which only cleaves polyUb with an unanchored C-terminal tail. In contrast, immunoblotting with the ubiquitin antibody showed that most of the polyUb chains associated with TAB2 were cleaved by IsoT. Similarly, immunoprecipitation experiments with an antibody against NEMO (also known as IKBKG), which is known to bind to polyUb chains to mediate IKK activation 15, 16 , showed that the polyUb chains associated with NEMO in the IL1b-stimulated cells were sensitive to IsoT treatment ( Supplementary Fig. 4) . These results indicate that IL1b induced rapid formation of polyUb chains that associated with TAB2 and NEMO, but were not conjugated to any target protein. Further experiments suggest that ubiquitination of IRAK1 or TRAF6 is dispensable for IKK activation (see Supplementary Information and Supplementary  Fig. 5 ), consistent with a recent report showing that a TRAF6 mutant lacking all lysine residues fully rescued IL1b-induced TAK1 and NF-kB activation in TRAF6-deficient cells 17 . One possible mechanism by which polyUb chains activate the TAK1 kinase complex is through the binding of polyUb to the TAB2 subunit; this binding may facilitate autophosphorylation of TAK1 at Thr 187, which is known to be important for TAK1 activation (Fig. 3c) 6 . To test this possibility, we expressed and purified kinase complexes containing wild type or a kinase-dead (Lys63Trp) mutant of TAK1. The two forms of TAK1 differ in size owing to a calmodulinbinding peptide appended to the amino terminus of the wild-type TAK1, allowing these proteins to be distinguished when probed with a TAK1 antibody. We incubated the wild-type and catalytically inactive TAK1 complex, both of which contained endogenous TAB2, in the presence of polyUb and ATP, and then measured the phosphorylation of TAK1 by immunoblotting. As shown in Fig. 3d , both wild-type and mutant TAK1 were phosphorylated at Thr 187 in the presence of polyUb when they were incubated together. Because TAK1(Lys63Trp) cannot phosphorylate itself, its phosphorylation at Thr 187 must have been carried out by the wild-type TAK1, suggesting that the TAK1 complexes are brought into close proximity by binding to polyUb. Alternatively, polyUb binding may allosterically activate the TAK1 complex.
The model proposed in Fig. 3c predicts that TAK1 activation by polyUb requires an intact ubiquitin-binding domain of TAB2 as well as Thr 187 of TAK1. Indeed, mutations of two conserved cysteine residues (C . A) within the novel zinc finger (NZF)-type ubiquitinbinding domain of TAB2 (ref. 12) severely impaired the activation of TAK1 by polyUb ( Fig. 3e) . Similarly, the TAK1(Thr187Ala) mutant failed to phosphorylate MKK6 in the presence of polyUb (Fig. 3f) .
Whereas TRAF6 did not undergo auto-polyubiquitination in the presence of UBC13-UEV1A in vitro, it was strongly polyubiquitinated in the presence of UBCH5C (Fig. 4a ). Immunoprecipitation of TRAF6 a, Ubiquitination reactions containing TRAF6 and UBC13-UEV1A or UBCH5C were analysed by immunoblotting with the indicated antibodies. b, Aliquots of reaction mixtures from a were denatured by heating in 1% SDS, then diluted to 0.1% SDS before immunoprecipitation with a TRAF6 antibody. c, PolyUb synthesized in the presence of TRAF6 and UBCH5C was pre-incubated with IsoT or its mutant Cys335Ala, then incubated with the IKK complex and IkBa to measure IKK activation. d, Polyubiquitinated TRAF6 (Ub n -TRAF6) was synthesized in the presence of UBCH5C, then incubated with the indicated DUBs before immunoblotting. e, Linear polyubiquitination of NEMO (Ub n -NEMO) was carried out in the presence of UBCH5C and RNF31-RBCK1 (E3), then Ub n -NEMO was incubated with the indicated DUBs followed by immunoblotting. Numbers to the left of each gel denote kDa.
under a denaturing condition confirmed that the polyUb chains were covalently attached to TRAF6 (Fig. 4b) . Interestingly, the polyubiquitination products synthesized in the presence of UBCH5C preferentially activated IKK, whereas those synthesized by UBC13 activated TAK1 ( Supplementary Fig. 6a, b ). Treatments of polyUb chains with IsoT effectively cleaved the unanchored polyUb chains, but not polyubiquitinated TRAF6 (Fig. 4c) . Notably, the IsoT treatment abrogated IKK activation, indicating that the UBCH5C-synthesized unanchored polyUb chains, but not ubiquitinated TRAF6, directly activated the kinase. A point mutation within a ubiquitin-binding domain of NEMO (Tyr308Ser) prevented IKK activation by unanchored polyUb chains in vitro ( Supplementary Fig. 7 ), suggesting that the polyUb chains activate IKK by directly binding to NEMO. The direct activation of IKK by TRAF6 and UBCH5C may explain the observations that the ablation of UBC13 in some mouse cell types prevents the activation of TAK1 and MAP kinases, but not IKK 18 , and that TAK1-deficient cells retain residual IKK activity 19 . Unlike UBC13-UEV1A, which catalyses specific Lys 63 polyUb chain synthesis 5, 20, 21 , UBCH5C promotes the synthesis of polyUb chains of various linkages, including Lys 48 and Lys 63. Indeed, neither the mutation of Lys 48 nor Lys 63 to arginine prevented polyUb chain synthesis or IKK activation by TRAF6 and Ubc5, whereas ubiquitin mutants containing a single lysine at position 48 or 63 failed to support polyUb-chain synthesis or IKK activation ( Supplementary Fig. 8 ). These results indicate that alternative ubiquitin linkages in the polyUb chains synthesized by TRAF6 and Ubc5 support IKK activation. A recent study suggests that linear ubiquitin chains, in which the N terminus of one ubiquitin is linked to the C terminus of the preceding ubiquitin, may mediate IKK activation 22 . However, we found no evidence that linear ubiquitin chains could efficiently activate TAK1 or IKK in vitro (see Supplementary Information and Supplementary Figs 9 and 10) .
Surprisingly, like IsoT, CYLD specifically removed unanchored polyUb chains, but not polyUb chains conjugated to TRAF6 (Fig. 4d ). To test whether CYLD could remove polyUb chains from another substrate, we carried out a ubiquitination reaction using UBCH5C and the RNF31 (also known as HOIP)-RBCK1 (also known as HOIL-1L) complex, which have been shown to function as E2 and E3, respectively, to catalyse linear polyubiquitination of NEMO 22 . Interestingly, CYLD and IsoT efficiently cleaved unanchored linear polyUb chains, but not the chains conjugated to NEMO (Fig. 4e) . In contrast, a deubiquitination enzyme containing the ovarian tumour (OTU) domain of the Crimean-Congo hemorrhagic fever virus (CCHFV) large (L) protein removed polyUb chains from NEMO, but not unanchored linear polyUb chains 23 (Fig. 4e, lane 6) . Further experiments indicated that the viral OTU, but not CYLD, was capable of cleaving Lys 63 polyUb chains from RIG-I (also known as DDX58), a viral RNA sensor 24 (see Supplementary Information and Supplementary Fig. 11 ). Taken together, these results indicate that CYLD preferentially cleaves unanchored polyUb chains in vitro. However, our data do not exclude the possibility that other proteins could assist CYLD in cleaving polyUb chains from protein targets or interfering with ubiquitination of these targets in vivo. Nevertheless, because the physiological function of CYLD in inhibiting TAK1 and IKK activation has been validated by abundant biochemical and genetic evidence 9 , our finding that CYLD preferentially cleaves unanchored polyUb chains further supports the role of these chains in protein kinase activation in the NF-kB pathway.
In much the same way that second messengers such as cyclic AMP are generated to activate protein kinases after stimulation of cells, unanchored polyUb chains are rapidly synthesized in cells stimulated with IL1b. Also like cAMP, which can be hydrolysed by phosphodiesterases, polyUb chains can be disassembled by specific deubiquitination enzymes, such as CYLD. The mechanism by which ubiquitin polymers activate protein kinases may be analogous to that used by polymeric nucleic acids, such as DNA and RNA, which bind to protein kinases containing nucleic-acid-binding domains or subunits (for example, DNA-dependent protein kinase or protein kinase R). It is known that the binding of double-stranded RNA polymers to protein kinase R leads to its dimerization and autophosphorylation 25, 26 . Similarly, we propose that the binding of unanchored polyUb chains to TAB2 or TAB3 leads to the dimerization or oligomerization of the TAK1 kinase complex, and subsequent autophosphorylation of TAK1 at Thr 187, resulting in TAK1 activation. We also suggest that binding of unanchored polyUb chains to NEMO leads to autophosphorylation and activation of the IKK complex.
METHODS SUMMARY
Expression plasmids, proteins, antibodies and cell lines are described in the Methods. The TAK1 kinase complex was affinity purified from a HEK293T cell line stably expressing a TAP-tagged TAK1. The IKK complex was purified from HeLa S100 by affinity and conventional chromatography. Lys 63-linked polyUb chains were synthesized in a reaction mixture containing UBC13-UEV1A and TRAF6, and then purified by affinity and conventional chromatography. Lys 48linked polyUb chains were synthesized using UBC3 (also known as CDC34) and the SKP1-CUL1-RBX1-bTrCP1 complex as the E2 and E3, respectively (bTrCP1 is also known as BTRC). The TAK1 and IKK activation assays were performed using polyUb chains as the activator. For deubiquitination experiments, polyUb chains were incubated with CYLD or IsoT. PolyUb chains induced by IL1b were isolated by immunoprecipitation with an antibody against TAB2 or NEMO, incubated with or without IsoT, and then analysed by immunoblotting. A detailed description of the experimental procedures is provided in the Methods.
Full Methods and any associated references are available in the online version of the paper at www.nature.com/nature.
